Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | PSMD10 | O75832 | 1/20 | 0.39 |
| ▸ | CYP24A1 | Q07973 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31281892 | 0.88 | TSHR (0.40) | TSHRALDH1A1PSMD10CYP24A1KDM4E | |
| SCHEMBL8211578 | 0.84 | ALDH1A1 (0.44) | TSHRALDH1A1PSMD10CYP24A1KDM4E | |
| SCHEMBL28634383 | 0.79 | CA12 (0.49) | CYP24A1KDM4ECA12CA1CA9 | |
| SCHEMBL29859619 | 0.78 | ALDH1A1 (0.46) | TSHRALDH1A1KDM4ESMN1; SMN2TDP1 | |
| SCHEMBL29860030 | 0.75 | ALDH1A1 (0.45) | TSHRALDH1A1KDM4EKCNH2SMN1; SMN2 | |
| SCHEMBL6647468 | 0.74 | CA1 (0.41) | ALDH1A1PSMD10CYP24A1KDM4ECA12 | |
| SCHEMBL24128057 | 0.73 | KCNH2 (0.40) | ALDH1A1KCNH2SMN1; SMN2 | |
| SCHEMBL27794804 | 0.73 | CA12 (0.46) | ALDH1A1KDM4ECA12CA1CA9 | |
| SCHEMBL5172102 | 0.73 | KDM4E (0.40) | TSHRALDH1A1KDM4ETDP1 | |
| SCHEMBL156710 | 0.73 | GAA (0.46) | ALDH1A1CA12CA1CA9SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7262185-B2 | Benzazepine derivative, process for producing the same, and use | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1422228-A1 | BENZAZEPINE DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2004-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235822-A1 | Benzazepine derivative, process for producing the same, and use | CYP1B1, CYP1A1, CYP2E1 | TSHR 2872/4885ALDH1A1 519/4885PSMD10 2408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.